Please upgrade your browser.
Technique using magnetic nanomaterials offers promise for diagnosis, gene therapy
“To see the impact that we make on the families around the area, with kidney cancer families, is always very rewarding,” tight end Adam Breneman said.
Many well-known pharmacy benefit managers and insurance companies, including Express Scripts, Catamaran, Optum, United HealthCare, and BCBS of various states, have made major changes to their coverage of prescribed compounded medicines.
Prof. Dr. Marniza Saad, Associate Professor and Consultant Oncologist at University Malaya Medical Centre
Dr. Robert Figlin describes a clinical trial for patients with advanced disease.
Recent report of MET inhibition strengthened the role of c–Met inhibition across pRCC.
Brian I. Rini, MD, presents a case study focused on the treatment of a 64 year-old male who presented with recurrent lung nodules 9 years after a left radical nephrectomy for a clear-cell renal cell carcinoma (RCC).
Patients with high cholesterol had a 43 percent lower risk of dying.
Phase 1 Cancer Trial for Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor for Solid Tumors
Deciphera Pharmaceuticals a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701). The Phase 1 trial will evaluate the safety tolerability and initial efficacy of altiratinib in cancer patients with solid tumors. Altiratinib has been shown to exhibit high potency and selectivity for inhibiting MET TIE2 VEGFR2 and TRK kinases in preclinical studies. A companion diagnostic assay will also be co-developed during the course of clinical studies.
Abstracts mentioning renal cell carcinoma (kidney cancer) from the 2014 ASCO Annual Meeting in Chicago.
|Powered by NeonCRM|